

Francesca M Carozzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5736604/publications.pdf>

Version: 2024-02-01

94
papers

6,430
citations

126858

33
h-index

66879

78
g-index

99
all docs

99
docs citations

99
times ranked

5541
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation of a centralized HPV-based cervical cancer screening programme in Tuscany: First round results and comparison with the foregoing Pap-based screening programme. <i>Journal of Medical Screening</i> , 2022, 29, 110-122.	1.1	3
2	Performance of <sc>HPV E6</sc>/<sc>E7 mRNA</sc> assay as primary screening test: Results from the <sc>NTCC2</sc> trial. <i>International Journal of Cancer</i> , 2022, 151, 1047-1058.	2.3	21
3	Prognostic selection and long-term survival analysis to assess overdiagnosis risk in lung cancer screening randomized trials. <i>Journal of Medical Screening</i> , 2021, 28, 39-47.	1.1	6
4	p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women. <i>Journal of the National Cancer Institute</i> , 2021, 113, 292-300.	3.0	41
5	Moderate-severe coronary calcification predicts long-term cardiovascular death in CT lung cancer screening: The ITALUNG trial. <i>European Journal of Radiology</i> , 2021, 145, 110040.	1.2	11
6	Smoking Cessation in the ITALUNG Lung Cancer Screening: What Does "Teachable Moment" Mean?. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1484-1491.	1.4	38
7	Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening. <i>International Journal of Cancer</i> , 2020, 147, 1864-1873.	2.3	16
8	HPV screening performance indicators in women who previously tested HPV-negative: The second round of Vallecmonica screening programme, Northern Italy. <i>Journal of Medical Screening</i> , 2020, 27, 207-214.	1.1	1
9	Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors. <i>Lung Cancer</i> , 2019, 138, 72-78.	0.9	15
10	Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. <i>International Journal of Cancer</i> , 2018, 143, 333-342.	2.3	16
11	Eurogin roadmap 2017: Triage strategies for the management of <sc>HPV</sc>-positive women in cervical screening programs. <i>International Journal of Cancer</i> , 2018, 143, 735-745.	2.3	124
12	Cost analysis of colorectal cancer screening with CT colonography in Italy. <i>European Journal of Health Economics</i> , 2018, 19, 735-746.	1.4	5
13	Cervical Cancer: Screening, Vaccination, and Preventive Strategies. , 2018, , .		0
14	Screen-detected multiple primary lung cancers in the ITALUNG trial. <i>Journal of Thoracic Disease</i> , 2018, 10, 1058-1066.	0.6	16
15	Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy. <i>BMC Infectious Diseases</i> , 2018, 18, 38.	1.3	35
16	Molecular Cytology Applications on Gynecological Cytology. , 2018, , 127-149.		2
17	Assessment of viral methylation levels for high risk HPV types by newly designed consensus primers PCR and pyrosequencing. <i>PLoS ONE</i> , 2018, 13, e0194619.	1.1	7
18	Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1056-1065.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. <i>Thorax</i> , 2017, 72, 825-831.	2.7	221
20	Multimodal lung cancer screening using the ITALUNG biomarker panel and low dose computed tomography. Results of the ITALUNG biomarker study. <i>International Journal of Cancer</i> , 2017, 141, 94-101.	2.3	25
21	Test methods for Textile Reinforced Mortar systems. <i>Composites Part B: Engineering</i> , 2017, 127, 121-132.	5.9	136
22	Interobserver reproducibility of cytologic p16 ^{INK4a} /Ki67 dual immunostaining in human papillomavirus-positive women. <i>Cancer Cytopathology</i> , 2017, 125, 212-220.	1.4	25
23	Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection. <i>Scientific Reports</i> , 2017, 7, 10200.	1.6	188
24	Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference. <i>Preventive Medicine</i> , 2017, 98, 21-30.	1.6	49
25	Does UKLS strategy increase the yield of screen-detected lung cancers? A comparison with ITALUNG: Table A1. <i>Thorax</i> , 2016, 71, 950-951.	2.7	6
26	Effectiveness of HPV vaccination in women reaching screening age in Italy. <i>Journal of Clinical Virology</i> , 2016, 84, 74-81.	1.6	11
27	Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms. <i>European Journal of Cancer</i> , 2016, 68, 148-155.	1.3	37
28	Reduced and Full-Preparation CT Colonography, Fecal Immunochemical Test, and Colonoscopy for Population Screening of Colorectal Cancer: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv319.	3.0	70
29	HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance. <i>Journal of Clinical Virology</i> , 2016, 76, S22-S28.	1.6	14
30	Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion. <i>Cancer Cytopathology</i> , 2016, 124, 66-67.	1.4	10
31	Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 201-212.	1.2	13
32	GISCi: an opportunity for more consideration and visibility for young researchers. <i>Epidemiologia E Prevenzione</i> , 2016, 40, 150.	1.1	0
33	Cervical cancer screening with HPV testing in the Valcamonica (Italy) screening programme. <i>Journal of Medical Screening</i> , 2015, 22, 38-48.	1.1	19
34	The Age Distribution of Type-Specific High-Risk Human Papillomavirus Incidence in Two Population-Based Screening Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 111-118.	1.1	11
35	Human papillomavirus prevalence in paired urine and cervical samples in women invited for cervical cancer screening. <i>Journal of Medical Virology</i> , 2015, 87, 508-515.	2.5	19
36	Extension of organized cervical cancer screening programmes in Italy and their process indicators, 2011-2012 activity. <i>Epidemiologia E Prevenzione</i> , 2015, 39, 61-76.	1.1	10

#	ARTICLE	IF	CITATIONS
37	A first survey of HPV-based screening in routine cervical cancer screening in Italy. <i>Epidemiologia E Prevenzione</i> , 2015, 39, 77-83.	1.1	21
38	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. <i>Lancet, The</i> , 2014, 383, 524-532.	6.3	1,282
39	Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence. <i>Journal of Clinical Virology</i> , 2014, 60, 257-263.	1.6	25
40	Screening for colorectal cancer with FOBT, virtual colonoscopy and optical colonoscopy: study protocol for a randomized controlled trial in the Florence district (SAVE study). <i>Trials</i> , 2013, 14, 74.	0.7	27
41	Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial. <i>BMC Infectious Diseases</i> , 2013, 13, 238.	1.3	19
42	Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. <i>Lancet Oncology, The</i> , 2013, 14, 168-176.	5.1	139
43	Codon 72 polymorphism of p53 and HPV type 16 E6 variants as risk factors for patients with squamous epithelial lesion of the uterine cervix. <i>Journal of Medical Virology</i> , 2013, 85, 83-90.	2.5	15
44	A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years. <i>BMC Infectious Diseases</i> , 2013, 13, 74.	1.3	20
45	Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for Cervical Cancer (NTCC) Study. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2901-2907.	1.8	26
46	Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1407-1412.	1.4	4
47	hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopy. <i>British Journal of Cancer</i> , 2013, 109, 1766-1774.	2.9	14
48	Four-Year Results of Low-Dose CT Screening and Nodule Management in the ITALUNG Trial. <i>Journal of Thoracic Oncology</i> , 2013, 8, 866-875.	0.5	114
49	Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates. <i>PLoS ONE</i> , 2013, 8, e81171.	1.1	21
50	HPV Testing Is an Efficient Management Choice for Women With Inadequate Liquid-Based Cytology in Cervical Cancer Screening. <i>American Journal of Clinical Pathology</i> , 2012, 138, 65-71.	0.4	11
51	Knowledge, attitude and practice in primary and secondary cervical cancer prevention among young adult Italian women. <i>Vaccine</i> , 2012, 30, 2075-2082.	1.7	45
52	Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. <i>European Journal of Cancer</i> , 2012, 48, 1633-1637.	1.3	50
53	HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies. <i>Infectious Agents and Cancer</i> , 2012, 7, 26.	1.2	19
54	Estimated acceptance of HPV vaccination among Italian women aged 18-26 years. <i>Vaccine</i> , 2011, 29, 8373-8380.	1.7	17

#	ARTICLE	IF	CITATIONS
55	The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). <i>British Journal of Cancer</i> , 2011, 104, 248-254.	2.9	106
56	Distribution of high and low risk HPV types by cytological status: a population based study from Italy. <i>Infectious Agents and Cancer</i> , 2011, 6, 2.	1.2	24
57	Association Between Genetic Polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT Genes and Radiosensitivity in Breast Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 52-58.	0.4	76
58	Comparison of Clinical Performance of Abbott RealTime High Risk HPV Test with That of Hybrid Capture 2 Assay in a Screening Setting. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1446-1451.	1.8	46
59	Human papillomavirus infection and risk factors in a cohort of Tuscan women aged 18-24: results at recruitment. <i>BMC Infectious Diseases</i> , 2010, 10, 157.	1.3	25
60	Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. <i>BMC Infectious Diseases</i> , 2010, 10, 214.	1.3	41
61	Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2389-2400.	1.1	64
62	Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis. <i>Journal of Medical Screening</i> , 2010, 17, 181-189.	1.1	20
63	Molecular profile in body fluids in subjects enrolled in a randomised trial for lung cancer screening: Perspectives of integrated strategies for early diagnosis. <i>Lung Cancer</i> , 2010, 68, 216-221.	0.9	19
64	Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. <i>Lancet Oncology</i> , The, 2010, 11, 249-257.	5.1	797
65	Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. <i>Lung Cancer</i> , 2009, 64, 34-40.	0.9	265
66	Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. <i>Lancet Oncology</i> , The, 2008, 9, 937-945.	5.1	170
67	Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. <i>Journal of the National Cancer Institute</i> , 2008, 100, 492-501.	3.0	259
68	Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 Assay in Detection of High-Risk Human Papillomavirus and Diagnosis of Biopsy-Confirmed High-Grade Cervical Disease. <i>Journal of Clinical Microbiology</i> , 2007, 45, 364-369.	1.8	35
69	HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. <i>European Journal of Cancer</i> , 2007, 43, 476-480.	1.3	65
70	The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. <i>Gynecologic Oncology</i> , 2007, 107, S230-S232.	0.6	17
71	Interlaboratory reproducibility of liquid-based equivocal cervical cytology within a randomized controlled trial framework. <i>Diagnostic Cytopathology</i> , 2007, 35, 541-544.	0.5	21
72	Human Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2006, 98, 765-774.	3.0	275

#	ARTICLE	IF	CITATIONS
73	Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. <i>Lancet Oncology</i> , The, 2006, 7, 547-555.	5.1	202
74	Interlaboratory reproducibility of atypical glandular cells of undetermined significance: a national survey. <i>Cytopathology</i> , 2006, 17, 353-360.	0.4	22
75	Reader variability in reporting breast imaging according to BI-RADS® assessment categories (the Tj ETQq1 1 0.784314 rgBT /Overlo 0.9 46	0.9	210
76	Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. <i>Cancer</i> , 2006, 108, 119-123.	2.0	34
77	Prognostic Significance of p53 and Ki-67 Antigen Expression in Surgically Treated Non-“Small Cell Lung Cancer. <i>American Journal of Clinical Pathology</i> , 2006, 125, 425-431.	0.4	22
78	Comparison of the Digene HC2 Assay and the Roche AMPLICOR Human Papillomavirus (HPV) Test for Detection of High-Risk HPV Genotypes in Cervical Samples. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2141-2146.	1.8	87
79	Categorizing breast mammographic density: intra- and interobserver reproducibility of BI-RADS density categories. <i>Breast</i> , 2005, 14, 269-275.	0.9	210
80	Analysis of morphologic patterns of fine-needle aspiration of the breast to reduce false-negative results in breast cytology. <i>Cancer</i> , 2005, 105, 152-157.	2.0	15
81	Technical evaluation of the new thin layer device cellslide®, (Menarini Diagnostics). <i>Diagnostic Cytopathology</i> , 2005, 33, 387-393.	0.5	2
82	Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. <i>American Journal of Clinical Pathology</i> , 2005, 124, 716-721.	0.4	90
83	Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. <i>American Journal of Clinical Pathology</i> , 2005, 124, 716-721.	0.4	54
84	Persistent Human Papilloma Virus Infection as an Indicator of Risk of Recurrence of High-Grade Cervical Intraepithelial Neoplasia Treated by the Loop Electrosurgical Excision Procedure. <i>Tumori</i> , 2004, 90, 225-228.	0.6	20
85	Comparing conventional and liquid-based smears from a consecutive series of 297 subjects referred to colposcopy assessment. <i>Cytopathology</i> , 2004, 15, 168-170.	0.4	6
86	Triage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessment. <i>Cancer</i> , 2004, 105, 2-7.	2.0	36
87	Association of human papillomavirus with prostate cancer: Analysis of a consecutive series of prostate biopsies. <i>International Journal of Biological Markers</i> , 2004, 19, 257-261.	0.7	25
88	Clinical impact (cost-effectiveness) of qualifying atypical squamous cells of undeterminate significance (ASCUS) in cases favoring a reactive or dysplastic process. <i>Diagnostic Cytopathology</i> , 2003, 29, 4-7.	0.5	3
89	A feasibility study of the use of the AutoPap screening system as a primary screening and location-guided rescreening device. <i>Cancer</i> , 2003, 99, 129-134.	2.0	19
90	Interlaboratory reproducibility of atypical squamous cells of undetermined significance report: a national survey. <i>Cytopathology</i> , 2003, 14, 263-268.	0.4	27

#	ARTICLE	IF	CITATIONS
91	Interlaboratory reproducibility of the immunocytochemical assessment of oestrogen and progesterone receptors and proliferative activity in fine needle aspiration of breast cancer. <i>Cytopathology</i> , 2002, 13, 92-100.	0.4	6
92	Analysis of False-Negative and Underreported Smears in the Florence District Screening Program for Cervical Carcinoma. <i>Tumori</i> , 1997, 83, 880-883.	0.6	4
93	A Quality Control System Involving Peer Review of Abnormal Cervical Smears. <i>Cytopathology</i> , 1993, 4, 17-25.	0.4	19
94	Partial trisomy 3q in a newborn female. <i>Research in Clinic and Laboratory</i> , 1977, 7, 225-32.	0.3	2